Excellis Insights offers a selection of Thought Leadership, SME knowledge, and white papers with the goal of being thoughtful, impactful, and most importantly- “actionable”. Our team of serialization, compliance, and project management experts provides deep understanding of the latest trends, issues, and regulatory changes to ensure you are on the path to compliance all while driving true business value.

U.S. FDA Guidance on DSCSA

FDA Guidance for COVID-19 Exemptions

Saleable Returns/VRS

DSCSA T3 Data Standardization and Documentation Practices

FDA Grandfathering Policy

FDA Guidance for Drug Supply Chain Security Act (DSCSA)

FDA Key Definitions for Suspect and Illegitimate Product Verification”

HDA Guidelines for Bar Coding in the Pharmaceutical Supply Chain”

OIG March 2018 Report: “Drug Supply Chain Security: Dispensers Received Most Tracing Information”

OIG September 2017 Summary: “Drug Supply Chain Security: Wholesalers Exchange Most Tracing Information”